IGF1R and Ewing sarcoma: The ORR with apatinib was 70% for ES, 40.9% for osteosarcoma, 100% for chondrosarcoma, and 71.4% for soft tissue sarcoma (Xie et al., 2018), indicating that combination therapy with IGF-1R may be therapeutically more efficient for cancer patients.